Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors
Iowa Research Online (The University of Iowa) · 12.04.2024
DOI: 10.25820/etd.007406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iowa Research Online (The University of Iowa), erschienen am 12.04.2024. Verfasst von Hayley R. Vaughn.
Abstract (Originalsprache)
Neuroendocrine tumors (NETs) are a heterogenous group of mainly epithelial neuroendocrine neoplasms with high metastatic potential. Up to 60% of patients have advanced metastatic liver disease at the time of diagnosis. Twelve to fifty percent of primary NETs in the abdomen are regularly missed due to small tumor size, body habitus, and abdominal gases. Of these, 50% originate in the pancreas (pNETs) and small bowel (sbNETs). Often located in close proximity, they are difficult to differentiate because of similar signs and symptoms, including abdominal pain, nausea, poor appetite, weight loss, and diarrhea. However, it is particularly important to differentiate between pNETs and sbNETs due to different treatment options and protocols.
Schlagwörter
Zitieren
APA
Vaughn, H. R. (2024). Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors. Iowa Research Online (The University of Iowa). https://doi.org/10.25820/etd.007406
Vancouver
Vaughn HR. Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors. Iowa Research Online (The University of Iowa). 2024. doi:10.25820/etd.007406
BibTeX
@article{Vaughn2024,
author = {Vaughn, Hayley R.},
title = {Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors},
journal = {Iowa Research Online (The University of Iowa)},
year = {2024},
doi = {10.25820/etd.007406}
}
EUVIMED